Zonisamid

Zonisamid
Klinički podaci
Prodajno ime	Exceglan, Excegram, Excegran, Zonegran
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	63 h
Identifikatori
CAS broj	68291-97-4
ATC kod	N03AX15 (WHO)
PubChem	CID 5734
DrugBank	DB00909
ChemSpider	5532
KEGG	C07504
ChEBI	CHEBI:10127
ChEMBL	CHEMBL750
Hemijski podaci
Formula	C8H8N2O3S
Molarna masa	212,226
	SMILES NS(=O)(=O)CC1=NOC2=CC=CC=C12; ;
	InChI InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) ; Key:UBQNRHZMVUUOMG-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	161—163 °C (322—325 °F)

Zonisamid je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 212,226 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	2
Particioni koeficijent^[13] (ALogP)	0,4
Rastvorljivost^[14] (logS, log(mol/L))	-2,2
Polarna površina^[15] (PSA, Å²)	94,6

Reference

^ Murata, M.; Horiuchi, E.; Kanazawa, I. (децембар 2001). . „Zonisamide has beneficial effects on Parkinson's disease patients”. Neuroscience Research. 41 (4): 397—9. PMID 11755227. S2CID 41685120. doi:10.1016/s0168-0102(01)00298-x.
^ Gadde, K. M.; Franciscy, D. M.; Wagner Hr, 2nd; Krishnan, K. R. (2003-04-09). . „Zonisamide for weight loss in obese adults: A randomized controlled trial”. JAMA. 289 (14): 1820—5. PMID 12684361. doi:10.1001/jama.289.14.1820.
^ Hasegawa, H. (мај 2004). . „Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: A retrospective, open label, uncontrolled study in a VA hospital”. Current Medical Research and Opinion. 20 (5): 577—80. PMID 15140322. S2CID 43580909. doi:10.1185/030079904125003313.
^ Leppik, I. E. (2004). . „Zonisamide: Chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5—9; discussion S10. PMID 15511691. S2CID 13458791. doi:10.1016/j.seizure.2004.04.016.
^ Ueda, Y.; Doi, T.; Tokumaru, J.; Willmore, L. J. (2003). . „Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures”. Brain Research. Molecular Brain Research. 116 (1–2): 1—6. PMID 12941455. doi:10.1016/s0169-328x(03)00183-9.
^ Farooq, M. U.; Moore, P. W.; Bhatt, A.; Aburashed, R.; Kassab, M. Y. (септембар 2008). . „Therapeutic role of zonisamide in neuropsychiatric disorders”. Mini Reviews in Medicinal Chemistry. 8 (10): 968—75. PMID 18782051. doi:10.2174/138955708785740643.
^ Schulze-Bonhage, A. (јануар 2010). . „Zonisamide in the treatment of epilepsy”. Expert Opinion on Pharmacotherapy. 11 (1): 115—26. PMID 20001433. S2CID 24881172. doi:10.1517/14656560903468728.
^ Kothare, S. V.; Kaleyias, J. (април 2008). . „Zonisamide: Review of pharmacology, clinical efficacy, tolerability, and safety”. Expert Opinion on Drug Metabolism & Toxicology. 4 (4): 493—506. PMID 18433351. S2CID 71773943. doi:10.1517/17425255.4.4.493.
^ Peters, D. H.; Sorkin, E. M. (мај 1993). . „Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy”. Drugs. 45 (5): 760—87. PMID 7686468. doi:10.2165/00003495-199345050-00010.
^ Sobieszek, G.; Borowicz, K. K.; Kimber-Trojnar, Z.; Małek, R.; Piskorska, B.; Czuczwar, S. J. (2003). . „Zonisamide: A new antiepileptic drug”. Polish Journal of Pharmacology. 55 (5): 683—9. PMID 14704463.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). . „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). . „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Zonisamide

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Murata, M.; Horiuchi, E.; Kanazawa, I. (децембар 2001). . „Zonisamide has beneficial effects on Parkinson's disease patients”. Neuroscience Research. 41 (4): 397—9. PMID 11755227. S2CID 41685120. doi:10.1016/s0168-0102(01)00298-x.

[2] Gadde, K. M.; Franciscy, D. M.; Wagner Hr, 2nd; Krishnan, K. R. (2003-04-09). . „Zonisamide for weight loss in obese adults: A randomized controlled trial”. JAMA. 289 (14): 1820—5. PMID 12684361. doi:10.1001/jama.289.14.1820.

[3] Hasegawa, H. (мај 2004). . „Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: A retrospective, open label, uncontrolled study in a VA hospital”. Current Medical Research and Opinion. 20 (5): 577—80. PMID 15140322. S2CID 43580909. doi:10.1185/030079904125003313.

[4] Leppik, I. E. (2004). . „Zonisamide: Chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5—9; discussion S10. PMID 15511691. S2CID 13458791. doi:10.1016/j.seizure.2004.04.016.

[5] Ueda, Y.; Doi, T.; Tokumaru, J.; Willmore, L. J. (2003). . „Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures”. Brain Research. Molecular Brain Research. 116 (1–2): 1—6. PMID 12941455. doi:10.1016/s0169-328x(03)00183-9.

[6] Farooq, M. U.; Moore, P. W.; Bhatt, A.; Aburashed, R.; Kassab, M. Y. (септембар 2008). . „Therapeutic role of zonisamide in neuropsychiatric disorders”. Mini Reviews in Medicinal Chemistry. 8 (10): 968—75. PMID 18782051. doi:10.2174/138955708785740643.

[7] Schulze-Bonhage, A. (јануар 2010). . „Zonisamide in the treatment of epilepsy”. Expert Opinion on Pharmacotherapy. 11 (1): 115—26. PMID 20001433. S2CID 24881172. doi:10.1517/14656560903468728.

[8] Kothare, S. V.; Kaleyias, J. (април 2008). . „Zonisamide: Review of pharmacology, clinical efficacy, tolerability, and safety”. Expert Opinion on Drug Metabolism & Toxicology. 4 (4): 493—506. PMID 18433351. S2CID 71773943. doi:10.1517/17425255.4.4.493.

[9] Peters, D. H.; Sorkin, E. M. (мај 1993). . „Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy”. Drugs. 45 (5): 760—87. PMID 7686468. doi:10.2165/00003495-199345050-00010.

[10] Sobieszek, G.; Borowicz, K. K.; Kimber-Trojnar, Z.; Małek, R.; Piskorska, B.; Czuczwar, S. J. (2003). . „Zonisamide: A new antiepileptic drug”. Polish Journal of Pharmacology. 55 (5): 683—9. PMID 14704463.

[11] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[12] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[13] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[14] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). . „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[15] Ertl, P.; Rohde, B.; Selzer, P. (2000). . „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]